

AMENDMENT

U.S. Appln. No. 09/722,438

sub D2 ~~58~~³ (Amended) ~~The substantially optically pure dextrorotatory isomer according to claim 57,~~ wherein the pharmaceutically acceptable salt is a salt of a mineral acid, or a substituted derivative thereof, selected from the group consisting of hydrochlorides, sulfates, nitrates, and phosphates.

C1 *sub D2* ~~59~~⁴ (Amended) ~~The substantially optically pure dextrorotatory isomer according to claim 57,~~ wherein the pharmaceutically acceptable salt is a salt of an organic acid, or a substituted derivative thereof, selected from the group consisting of acetates, propionates, succinates, benzoates, fumarates, tartrates, theophyllineacetates, salicylates, and phenolphthalinates.

sub D1 ~~60~~² (Amended) A pharmaceutical composition comprising an effective amount of the ~~substantially optically pure dextrorotatory isomer of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)-carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine,~~ or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

C2 ~~61~~⁵ (Amended) The pharmaceutical composition according to claim ~~60~~², wherein the pharmaceutically acceptable salt is a salt of a mineral acid, or a substituted derivative thereof, selected from the group consisting of hydrochlorides, sulfates, nitrates, and phosphates.

~~62~~⁶ (Amended) The pharmaceutical composition according to claim ~~61~~⁵, wherein the pharmaceutically acceptable salt is a salt of an organic acid, or a substituted derivative thereof, selected from the group consisting of acetates, propionates, succinates, benzoates, fumarates, tartrates, theophyllineacetates, salicylates, and phenolphthalinates.

AMENDMENT

U.S. Appln. No. 09/722,438

¹66. (Amended) The pharmaceutical composition according to claim ²63, wherein the therapeutically effective amount of ~~the substantially optically pure dextrorotatory isomer of~~ 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)-carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, or a pharmaceutically acceptable salt thereof, is from about 2.5 mg to about 15 mg.

⁸67. (Amended) The pharmaceutical composition according to claim ²63, wherein the pharmaceutically acceptable carrier comprises a diluent.

Please add the following additional claim:

³68. (New) 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, or a pharmaceutically acceptable salt thereof, in the form of its dextrorotatory isomer and essentially free of its levorotatory isomer.--